Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimizing Lymph Node Staging in Esophageal Cancer with USPIO-enhanced MRI
2023-506952-26-01Phase 2Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Jul 2025
- Modality
- Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ferumoxtran-10 in esophageal adenocarcinoma (EAC), sponsored by Amsterdam University Medical Center. Primary endpoints: Observer’s qualitative assessment of image quality for evaluation of lymph node metastases on USPIO-enhanced MRI, compared to PET-CT images, Time required for observers to assess USPIO-enhanced MRI, compared to standard PET-CT and 3 more. Planned start Jul 2025; status: authorised.
02
Drugs
ferumoxtran-10
03
Conditions
esophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2023-506952-26-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506952-26-01.